GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
ST. JOSEPH, Mich., September 25, 2007 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that Bristol-Myers Squibb has licensed access to all major GeneGo products. Using the licensed GeneGo technology, research and development sites within Bristol-Myers Squibb will have the ability to start with chemical compound structures and/or genomics data to address questions from both chemistry and biology domains. Bristol-Myers Squibb can also access GeneGo tools to build their own canonical pathway maps using public, GeneGo, and proprietary data and have those maps included in statistical calculations and overlays. In addition, Bristol Myers Squibb researchers can leverage GeneGo products to overlay their own internal interaction data in the context of manually curated pathways for more elucidation.
"Bristol Myers Squibb is very important to GeneGo as they have excellent scientists who we have been collaborating with," said Julie Bryant, GeneGo's VP of Business Development. "We plan to continue this collaborative spirit over the next few years."
GeneGo develops systems biology technology for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 5.0(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug2.0(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at http://www.genego.com.
MetaCore(TM), MetaBase(TM), MetaDrug(TM) , MetaLink(TM), MetaDiscovery(TM), MetaTox(TM) and MetaMiner(TM) , 1-2-3 Workflow(TM) are trademarks of GeneGo, Inc.
CONTACT: Lina Nihiser, Marketing of GeneGo, Inc., +1-858-756-7996, email@example.com
Web site: http://www.genego.com/
Ticker Symbol: (NYSE:BMY)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: September 2007
Recommended for you